These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 37408777)
41. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer. Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869 [TBL] [Abstract][Full Text] [Related]
42. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma. Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375 [TBL] [Abstract][Full Text] [Related]
43. Tian WJ; Feng PH; Wang J; Yan T; Qin QF; Li DL; Liang WT Front Mol Biosci; 2021; 8():583028. PubMed ID: 33869272 [TBL] [Abstract][Full Text] [Related]
44. Identification and validation of a novel zinc finger protein-related gene-based prognostic model for breast cancer. Ye M; Li L; Liu D; Wang Q; Zhang Y; Zhang J PeerJ; 2021; 9():e12276. PubMed ID: 34721975 [TBL] [Abstract][Full Text] [Related]
45. A mitochondrial function-related LncRNA signature predicts prognosis and immune microenvironment for breast cancer. Wang Y; Gao S; Xu Y; Tang Z; Liu S Sci Rep; 2023 Mar; 13(1):3918. PubMed ID: 36890266 [TBL] [Abstract][Full Text] [Related]
46. Identification of a tumor immune-inflammation signature predicting prognosis and immune status in breast cancer. Liu Y; Ouyang W; Huang H; Tan Y; Zhang Z; Yu Y; Yao H Front Oncol; 2022; 12():960579. PubMed ID: 36713514 [TBL] [Abstract][Full Text] [Related]
47. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399 [TBL] [Abstract][Full Text] [Related]
48. Identification and Validation of an Immune-Related eRNA Prognostic Signature for Hepatocellular Carcinoma. Cai S; Hu X; Chen R; Zhang Y Front Genet; 2021; 12():657051. PubMed ID: 34178028 [TBL] [Abstract][Full Text] [Related]
49. Identification and validation of a five-gene prognostic signature based on bioinformatics analyses in breast cancer. Du XJ; Yang XR; Wang QC; Lin GL; Li PF; Zhang WF Heliyon; 2023 Feb; 9(2):e13185. PubMed ID: 36747547 [TBL] [Abstract][Full Text] [Related]
50. N6-methyladenosine Regulator-Mediated Immune Genes Identify Breast Cancer Immune Subtypes and Predict Immunotherapy Efficacy. Zhang MM; Lin YL; Zeng WF; Li Y; Yang Y; Liu M; Ye YJ; Jiang KW; Wang S; Wang S Front Genet; 2021; 12():790888. PubMed ID: 34976022 [TBL] [Abstract][Full Text] [Related]
51. Deciphering the nexus between the tumor immune microenvironment and DNA methylation in subgrouping estrogen receptor-positive breast cancer. Chen XQ; Zhang F; Xiao FH; Peng Y Breast Cancer; 2021 Nov; 28(6):1252-1260. PubMed ID: 33966175 [TBL] [Abstract][Full Text] [Related]
52. TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy. Zhu X; Yuan Z; Cheng S; Wang H; Liao Y; Zhou D; Wu Z World J Surg Oncol; 2022 Oct; 20(1):336. PubMed ID: 36207751 [TBL] [Abstract][Full Text] [Related]
53. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma. Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566 [TBL] [Abstract][Full Text] [Related]
54. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC. Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648 [TBL] [Abstract][Full Text] [Related]
55. Constructing a novel prognostic signature of tumor driver genes for breast cancer. Zhou L; Yi Y; Liu C; Chen Z Am J Transl Res; 2022; 14(7):4515-4531. PubMed ID: 35958490 [TBL] [Abstract][Full Text] [Related]
56. A novel immune-related prognostic index for predicting breast cancer overall survival. Yu X; Guo J; Zhou Q; Huang W; Xu C; Long X Breast Cancer; 2021 Mar; 28(2):434-447. PubMed ID: 33146847 [TBL] [Abstract][Full Text] [Related]
57. The prognostic value and response to immunotherapy of immunogenic cell death-associated genes in breast cancer. Zhao R; Wang W; Pan L; Lv X; He Y; Lian W; Ma Y; Zhang X; Yu R; Zhao S; Guo X; Huang T; Peng M Front Oncol; 2023; 13():1047973. PubMed ID: 36845750 [TBL] [Abstract][Full Text] [Related]
58. The molecular feature of macrophages in tumor immune microenvironment of glioma patients. Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502 [TBL] [Abstract][Full Text] [Related]
59. Weighted Gene Coexpression Network Analysis Identifies TBC1D10C as a New Prognostic Biomarker for Breast Cancer. Qiao H; Lv R; Pang Y; Yao Z; Zhou X; Zhu W; Zhou W Anal Cell Pathol (Amst); 2022; 2022():5259187. PubMed ID: 35425695 [TBL] [Abstract][Full Text] [Related]
60. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer. Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]